Bio Vet Innovator Magazine

Volume 2 (Issue 10) OCTOBER 2025

OPEN ACCESS POPULAR ARTICLE

Nature's Mycochemists: Harnessing Fungal Metabolites for Next-Gen Medicine

Vaidehi D. Chandankar
Department of Veterinary Microbiology,
ICAR-Indian Veterinary Research Institute,
Bengaluru, Karnataka, India 560024
***Corresponding Author:** chandankarvaidehi@gmail.com
DOI: https://doi.org/10.5281/zenodo.17527697

Received: October 31, 2025
Published: November 04, 2025
© All rights are reserved by **Vaidehi D. Chandankar**

Abstract:

Fungi are master chemists, producing a diverse array of secondary metabolites with profound implications for human and veterinary health. While many fungal metabolites, such as aflatoxins, ochratoxins, and fumonisins, pose serious toxic risks, others have revolutionized medicine as antibiotics, anticancer agents, immunomodulators, cardiovascular drugs, CNS-active compounds, and antivirals. Landmark metabolites include Penicillin's, cephalosporins, paclitaxel, statins, cyclosporine A, and fingolimod, demonstrating fungi's unique potential to combat bacterial infections, cancers, autoimmune disorders, and neurological diseases. Emerging research emphasizes the discovery of novel bioactive compounds through fungal bioprospecting, endophytic exploration, and targeted screening for veterinary and human applications. Fungal metabolites now offer solutions against infections, cancer, autoimmune disorders, cardiovascular and CNS diseases, and viral threats. Emerging research focuses on discovering novel compounds through fungal bioprospecting and endophytes, promising next-generation therapeutics for human and veterinary health.

Keywords: Fungi, Penicillin, Fungal Metabolites, Mycotoxins

Introduction:

Fungi cause a wide range of infections in humans, affecting over a billion people worldwide, from mild allergies to life-threatening invasive fungal infections (IFIs). The problem is growing, worsened by new fungal pathogens, resistant strains, and re-emergence of rare diseases. True prevalence is hard to measure due to diagnostic challenges, but a review estimated 6.5 million IFIs annually, leading to around 2.5 million deaths.

Fungi are also remarkable producers of natural compounds called secondary metabolites, which show various biological activities. These metabolites can be toxic mycotoxins or non-toxic beneficial compounds. Mycotoxins contaminate food and pose health risks to humans and animals, affecting organs

through carcinogenic, immunosuppressive, hepatotoxic, nephrotoxic, and neurotoxic effects. Hundreds of mycotoxins are known with major concerns including aflatoxin B1 and M1, cyclopiazonic acid, ochratoxin A, patulin, T-2 toxin, deoxynivalenol, zearalenone, ergot alkaloids, and macrocyclic trichothecenes due to their health and economic impact. Aflatoxin B1 is considered the most potent liver carcinogen and mutagen. Human exposure is likely underestimated, highlighting the need to discover more toxic fungal metabolites linked to unknown diseases.

On the other hand, some fungal metabolites are beneficial, such as antibiotics used to treat human diseases. Researchers study these metabolites' regulation, function, applications, and toxicity. Over 1,500 fungal metabolites have been isolated, with half already used in healthcare, while the rest are still under safety evaluation.

Fungal Secondary Metabolites: Dual Faces of Nature's Chemistry

While fungi are widely known for causing infections in humans, they also possess a fascinating and often overlooked side — that of skilled natural chemists capable of producing a remarkable array of secondary metabolites (SMs), some harmful (mycotoxins) and others beneficial (antibiotics). These compounds help fungi interact with their environment, survive, and communicate, but are not required for reproduction.

The Dark Side: Fungal Threats

Toxic Metabolites (Mycotoxins):

The term *mycotoxin* was first introduced in 1960, derived from "myco" (fungus) and "toxin" (poison), referring to toxic secondary metabolites produced by certain fungi on food commodities such as grains, nuts, and spices under warm, humid conditions. They can appear at any stage preharvest, postharvest, or storage and resist most processing, posing serious health and economic risks. Exposure via contaminated food, inhalation, or contact can cause organ damage, immune suppression, reproductive issues, and even cancer in humans. Globally, mycotoxins affect ~25% of grains, destroying nearly a billion tonnes of food annually.

Major toxins include aflatoxins, ochratoxins, fumonisins, trichothecenes, zearalenone, and ergot alkaloids, produced by *Aspergillus*, *Fusarium*, and *Penicillium*. Aflatoxins notably cause deaths in humans, especially in Africa, while animals suffer reduced feed intake, poor growth, reproductive disorders, and organ damage, leading to significant economic losses.

- ***Aflatoxins:***

  Produced mainly by *Aspergillus flavus* and *A. parasiticus*, aflatoxins accumulate in the body and cause liver damage, hepatocellular carcinoma (HCC), immune suppression, and growth impairment in humans and animals.

  AFB1 is the most toxic, responsible for acute aflatoxicosis and long-term carcinogenic effects across

multiple species.

- ***Ochratoxin A (OTA):***

  Produced by *Penicillium verrucosum* and *Aspergillus* species. OTA accumulates in blood and milk, causing kidney damage, liver and heart lesions, reproductive toxicity, and immunosuppression in animals.

  Maternal exposure can affect foetal development; although human risk is generally low, extremely high exposures may increase nephritic syndrome incidence.

- ***Fumonisins:***

  Produced mainly by *Fusarium verticillioides*, *F. proliferatum*, and *A. niger*, fumonisins disrupt sphingolipid metabolism, causing liver and kidney damage, leukoencephalomalacia in horses, and pulmonary edema in swine.

  In humans, high exposure is linked to esophageal cancer and neural tube defects; FB1 is the most common and toxic form

Opportunistic Fungal Pathogens:

In the Indian subcontinent, certain environmental fungi are particularly significant because of the large number of cases they cause. These include *Aspergillus* species, the agents of mucormycosis, *Cryptococcus*, *Histoplasma*, and *Sporothrix* species, along with the diverse fungi responsible for mycetoma, all of which contribute substantially to the national disease burden.

They can cause skin lesions (nodules, ulcers, necrosis), respiratory issues (fever, cough, dyspnea), neurological symptoms (meningeal signs, confusion), and systemic conditions like candidemia, pulmonary infections, and disseminated mucormycosis.

Fungi as Natural Chemists:

Fungal SMs include alkaloids, terpenoids, polyketides, and non-ribosomal peptides (NRPs). They are produced via metabolic pathways starting from acetyl-CoA,5 forming compounds like carotenoids and aflatoxins.

SMs form at different growth stages or in response to environmental cues, fulfilling ecological roles such as defense, interspecies communication, and competition. Their structural diversity and biological activity make them important in health, pharmaceuticals, and biotechnology. Some fungal SMs show antibacterial, antifungal, and immunosuppressive activities, and are used in the development of antibiotics, immunosuppressants, and anticancer drugs.

Important Fungal Secondary Metabolites in Healthcare:

Sr. No.	Fungal SMs	Source Fungus	Application	Medical/Pharmaceutical Benefits
1.	**Penicillin**	Penicillium notatum, P. chrysogenum	Antibiotic	Broad-spectrum antibiotics are effective against bacterial infections like pneumonia, sepsis, and syphilis

2.	**Aflatoxins**	Aspergillus flavus, A. parasiticus	Research tool in oncology	Though toxic, aflatoxins are used in cancer research to study liver carcinogenesis and detoxification processes
3.	**Cephalosporins**	Acremonium chrysogenum	Antibiotic	Treats bacterial infections like bronchitis, pneumonia, and skin infections, similar to penicillin but broader
4.	**Cordycepin**	Cordyceps militaris	Anticancer and anti-inflammatory agent	Shows potential in cancer therapy by inhibiting RNA synthesis and demonstrates anti-inflammatory and antioxidant properties
5.	**Ergotamine**	Claviceps purpurea	Vaso-constrictor	Used in the treatment of migraines and cluster headaches by constricting blood vessels
6.	**Griseofulvin**	Penicillium griseofulvum	Antifungal agent	Treats fungal infections of the skin, hair, and nails, such as athlete's foot and ringworm
7.	**Penicillin**	Penicillium notatum, P. chrysogenum	Antibiotic	broad-spectrum antibiotics are effective against bacterial infections like pneumonia, sepsis, and syphilis

Table 1. Key Fungal Metabolites with Pharmaceutical Applications

Next-Generation Medicine:

Emerging fungal metabolites, including anticancer, antiviral, and immunosuppressive compounds, are showing great potential for human and veterinary applications. Current research focuses on screening diverse fungi, bioprospecting novel compounds, and harnessing these metabolites to develop innovative therapeutics. These trends highlight a promising, forward-looking path for next-generation medicine.



Figure 1: Therapeutic Potential of Fungal Secondary Metabolites

Fungal Metabolites Used as Antibiotics:

- Many filamentous fungi produce compounds that inhibit bacterial and fungal pathogens, though most clinical antibiotics come from *Streptomyces* and actinobacteria.
- Penicillins (*Penicillium*) and cephalosporins (*Cephalosporium*) revolutionized medicine and remain essential antibiotics for ~70 years.
- Mycophenolic acid, discovered in 1893 from *Penicillium brevicompactum*, was initially an antibiotic but

is now used as an immunosuppressant due to toxicity.

- New fungal metabolites like coprinuslactone (*Coprinus comatus*) and roussoellenic acid (*Roussoella* spp.) target biofilms, offering hope against antibiotic-resistant pathogens.

Fungal Metabolites Used as Anticancer Agents:

- Illudin S (*Omphalotus illudens*) and its derivative Irofulven disrupt DNA replication, showing anticancer activity against multiple human cancer cell lines, including brain, breast, colon, ovarian, and pancreatic cancers.
- Aphidicolin (*Akanthomyces muscarius*) is a tetracyclic diterpene with antimitotic properties, still under intensive clinical trials.
- Paclitaxel (Taxol), initially from *Taxus brevifolia*, later produced by endophytic fungi like *Taxomyces andreanae*, is FDA-approved for breast and ovarian cancers; fungal sources solved supply limitations.

Fungal Metabolites Used as CNS-Disease-Related Agents:

- Hericium erinaceus produces hericenones and erinacines, which stimulate nerve growth factor synthesis and promote nerve regeneration in vitro and in vivo.
- Fingolimod (*Isaria sinclairii*) is an immunosuppressant FDA-approved in 2010 for treating multiple sclerosis.
- Ergotamine (*Claviceps purpurea*) is a vasoconstrictor alkaloid used to prevent postpartum hemorrhage and treat acute migraine attacks.

Fungal Metabolites Controlling Cardiovascular Diseases:

- Statins inhibit HMG-CoA reductase, reducing plasma cholesterol and lowering cardiovascular disease risk.
- Compactin (Mevastatin, ML-236B) from *Penicillium brevicompactum* showed early hypocholesterolemic activity.
- Lovastatin, FDA-approved, is mainly produced commercially from *Aspergillus terreus*.

Fungal Metabolites as Immunomodulatory Agents:

- Cyclosporine A from *Tolypocladium inflatum* binds cyclophilin A → inhibits calcineurin → suppresses IL-2 production → used in organ transplant immunosuppression.
- Mycophenolic acid from *Penicillium* spp. inhibits IMPDH → suppresses T- and B-cell proliferation; prevents tissue damage via tetrahydrobiopterin depletion.
- Mycophenolate mofetil (prodrug) is clinically used to prevent organ rejection and treat autoimmune disorders.

Fungal Metabolites Used as Antiviral Agents:

- Hinnuliquinone - bis-indolyl quinone from a Quercus coccifera-associated fungus; inhibits HIV-1 protease, including drug-resistant strains.

Citation: Vaidehi D. Chandankar. (2025). Nature's Mycochemists: Harnessing Fungal Metabolites for Next-Gen Medicine. In Bio Vet Innovator Magazine (Vol. 2, Issue 10, pp. 20–26). Bio Vet Innovator Magazine. https://doi.org/10.5281/zenodo.17527697

- Stachybosin D – phenylspirodrimane from sponge-derived *Stachybotrys chartarum*; inhibits HIV-1 replication by targeting reverse transcriptase.
- Stachyflin – terpenoid from marine *Stachybotrys* spp.; active against influenza A virus (H1N1).
- Vanitaracin A – tricyclic polyketide from *Talaromyces* spp.; blocks entry of all HBV genotypes (A–D) and affects hepatitis D virus.
- Rhodatin – novel meroterpenoid from *Rhodotus palmatus*; shows strong anti-HCV activity.

Conclusion:

Once seen merely as pathogens, fungi have now earned recognition as nature's master chemists. Their secondary metabolites have redefined medicine — from the penicillin revolution to the discovery of statins, cyclosporine, and paclitaxel that transformed therapies for infections, heart disease, and cancer. Each metabolite reflects nature's precision, often surpassing synthetic drugs in potency and selectivity.Today, as antimicrobial resistance and complex diseases rise, fungi continue to reveal powerful bioactive compounds through advances in genomics and metabolomics. Endophytic and marine fungi, in particular, promise novel antivirals, neuroprotective, and veterinary agents. Truly, fungi stand as *silent innovators* — shaping the next generation of therapeutics that unite human and animal health.

References:

Bills, G.F. and Gloer, J.B., 2016. Biologically active secondary metabolites from the fungi. *Microbiology spectrum*, 4(6).

Denning, D.W., 2024. Global incidence and mortality of severe fungal disease. *The Lancet Infectious* Diseases, 24(7).

Feng, Y., Huang, Y., Zhan, H., Bhatt, P. and Chen, S., 2020. An overview of strobilurin fungicide degradation: current status and future perspective. *Frontiers in microbiology*, 11.

Janik, E., Niemcewicz, M., Ceremuga, M., Stela, M., Saluk-Bijak, J., Siadkowski, A. and Bijak, M., 2020. Molecular aspects of mycotoxins—A serious problem for human health. *International journal of molecular sciences*, 21(21)

Kaneria, M., Rakholiya, K., Bavaliya, K.R., Pandya, M.H., Sipai, T.N., Vadher, S.A., Patel, M., Yadav, V.K., Solanki, R., Patel, S. and Sahoo, D.K., 2024. Untargeted metabolomics-based identification of bioactive compounds from Mangifera indica L. seed extracts in drug discovery through molecular docking and assessment of their anticancer potential. *Journal of the Science of Food and Agriculture*, 104(10).

Mollayusefian, I., Ranaei, V., Pilevar, Z., Cabral-Pinto, M.M., Rostami, A., Nematolahi, A., Khedher, K.M., Thai, V.N., Fakhri, Y. and Khaneghah, A.M., 2021. The concentration of aflatoxin M1 in raw and pasteurized milk: A worldwide systematic review and meta-analysis. *Trends in Food Science & Technology*, 115.

Moonjely, S., 2022. Fungi: essential elements in the ecosystems. In *The Impact of Climate Change on Fungal Diseases*.

Naranjo-Ortiz, M.A. and Gabaldón, T., 2020. Fungal evolution: cellular, genomic and metabolic complexity. *Biological Reviews*, 95(5).

Sandargo, B., Michehl, M., Praditya, D., Steinmann, E., Stadler, M. and Surup, F., 2019. Antiviral meroterpenoid rhodatin and sesquiterpenoids rhodocoranes A–E from the Wrinkled Peach Mushroom, Rhodotus palmatus. *Organic letters*, 21(9).

Sarmast, E., Fallah, A.A., Jafari, T. and Khaneghah, A.M., 2021. Impacts of unit operation of cheese manufacturing on the aflatoxin M1 level: A global systematic review and meta-analysis. *Lwt*, 148.

Stierle, A.A. and Stierle, D.B., 2015. Bioactive secondary metabolites produced by the fungal endophytes of conifers. *Natural product communications*, 10(10).

Wißfeld, J., Hering, M., Ten Bosch, N. and Cui, G., 2024. The immunosuppressive drug cyclosporin A has an immunostimulatory function in CD8+ T cells. *European Journal of Immunology*, 54(7).